COMMUNIQUÉS West-GlobeNewswire

Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
03/12/2024
HRC Fertility to begin providing FemaSeed infertility treatment to patients at centers across California ATLANTA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on [...]
Aeroflow Health Announces Giving Tuesday Donations to Organizations in Western North Carolina
03/12/2024
Aeroflow donates a total of $25,000 across five local organizations based in its home state ASHEVILLE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge [...]
Soda Health closes oversubscribed $50M Series B led by General Catalyst to scale its Smart Benefits Operating System
03/12/2024
The fundraise will enable Soda Health to broaden its offering of data products and services, and expand its support to new benefit categories BENTONVILLE, Ark., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Soda Health , a health [...]
Alira Health Unveils 2024 Report on Antibody-Drug Conjugates Market
03/12/2024
Analysis projects 21% annual growth, with global sales expected to reach $39 billion by 2030. FRAMINGHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Alira Health, a global advisory and clinical research firm dedicated to [...]
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
03/12/2024
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI [...]
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
03/12/2024
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCONx Conference
03/12/2024
CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7 th Annual Evercore ISI HealthCONx [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/12/2024
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]
Revolution Medicines Announces Commencement of Public Offering of Common Stock
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
MacroGenics to Participate in Upcoming Investor Conference
02/12/2024
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody- [...]
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024
02/12/2024
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024
02/12/2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Treace Appoints Guy Guglielmino as Chief Commercial Officer
02/12/2024
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Certara Showcases 2024 Research Wins With Over 100 Papers Published
02/12/2024
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list RADNOR, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed [...]
Capricor Therapeutics to Present at Upcoming Investor Conferences
02/12/2024
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
02/12/2024
Reimbursement approval supports expanded access to effective, safe thrombus removal for patients suffering from deep vein thrombosis (DVT) in Japan IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. ( [...]
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
02/12/2024
Upon closing, the transaction would secure global IP rights for NKGen. NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer (“NK”) cell therapy is already [...]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
02/12/2024
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral [...]

Pages